Trius Therapeutics (TSRX)
Add to Watchlists Create an Alert
7.88
-0.02 -0.25%
NASDAQ
May 24, 10:36AM
BATS Real time
Currency in USD
Trius Therapeutics Revenue Quarterly:
1.727M for Dec. 31, 2012Trius Therapeutics Historical Revenue Quarterly Data
Pro Data Export
Dates:
to
There is no data for the selected date range.
| Data for this Date Range | |
|---|---|
| March 31, 2013 | 1.727M |
| Dec. 31, 2012 | 5.156M |
| Sept. 30, 2012 | 5.973M |
| June 30, 2012 | 6.224M |
| March 31, 2012 | 9.832M |
| Dec. 31, 2011 | 5.002M |
| Sept. 30, 2011 | 30.44M |
| June 30, 2011 | 2.859M |
| March 31, 2011 | 2.715M |
| Dec. 31, 2010 | 2.521M |
| Sept. 30, 2010 | 1.94M |
| June 30, 2010 | 2.084M |
| March 31, 2010 | 1.486M |
| Dec. 31, 2009 | 1.032M |
| Sept. 30, 2009 | 1.691M |
| June 30, 2009 | 1.209M |
| March 31, 2009 | 1.085M |
| Dec. 31, 2008 | 0.65M |
About Revenues
Income that a company gains from business activities, calculated before any expenses are subtracted. Includes all sales and other increases in owner's equity. Increasing revenues over time are generally a good sign of company's growth.
While a bit obvious, if a lemonade company has sold 30 million in revenue and has 10 million in costs of goods sold, the company's revenue is still 30 million. (Expenses are not accounted in Revenue).
Learn More
TSRX Revenue Quarterly Benchmarks
| Companies | |
|---|---|
| Genomic Health | 63.09M |
| Acorda Therapeutics | 71.86M |
| Chembio Diagnostics | 7.866M |
TSRX Revenue Quarterly Rankings
| Overall |
42nd percentile 4604 of 8009 |
| Sector |
39th percentile 416 of 687 in Healthcare |
| Industry |
33rd percentile 43 of 65 in Diagnostics & Research |
TSRX Revenue Quarterly Range, Past 5 Years
| Minimum | 0.6500M | Dec 2008 |
| Maximum | 30.44M | Sep 2011 |
| Average | 4.646M |
TSRX News
Trius Therapeutics (TSRX) Tedizolid Phosphate Portfolio Receives NoA from UPTO
Street Insider May 13
Street Insider May 13